$CRNX

Crinetics Pharmaceuticals, Inc. filed a Form 15 with the SEC to terminate its registration under the Securities Exchange Act of 1934. The company cited Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i) as the basis for this termination, which is effective as of September 11, 2026. The filing indicates that the company has one holder of record. Charles Wagner, President of Crinetics Pharmaceuticals, Inc., signed the document.

Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (CRNX), delisting it from Nasdaq. Crinetics is now a subsidiary, with leadership changes announced. The $10B deal was funded by cash, debt, and $4.5B in bridge financing. Vertex gains exposure to Crinetics' endocrine disease treatments. Investors should watch for updates on pipeline and commercial priorities.

Crinetics Pharmaceuticals (CRNX) director Vivaldi Coelho Rogerio reported disposing of stock and options on September 1, 2026, following the company's merger with Vertex Pharmaceuticals. Each Crinetics share was converted into $85.00 in cash. The director's dispositions included common stock, restricted stock units, and stock options, all converted according to the merger terms.

WIERENGA WENDELL sold (to issuer) 122,071 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($10.38M total) across 2 trades on 2026-09-01.

Vivaldi Coelho Rogerio sold (to issuer) 19,225 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.63M total) across 2 trades on 2026-09-01.

Crinetics Pharmaceuticals (CRNX) director Weston Nichols received $85 per share in cash as part of the company's merger with Vertex Pharmaceuticals. His stock options were canceled, with those below $85 exercise price converted to cash, while others received no consideration. The merger was effective September 1, 2026.

Okey Stephanie sold (to issuer) 12,325 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.05M total) across 2 trades on 2026-09-01.

Nichols Weston sold (to issuer) 22,225 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.89M total) across 2 trades on 2026-09-01.

Fust Matthew K sold (to issuer) 28,761 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($2.44M total) across 2 trades on 2026-09-01.

Deardorf Caren sold (to issuer) 22,225 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.89M total) across 2 trades on 2026-09-01.